Abstract
Introduction: The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists.
Methods: EUFIND combined consensus workshops and data sharing for multisite analysis, focusing on 7 core topics: clinical applications/clinical research, highest resolution anatomy, functional imaging, vascular systems/vascular pathology, iron mapping and neuropathology detection, spectroscopy, and quality assurance. Across these topics, EUFIND considered standard operating procedures, safety, and multivendor harmonization.
Results: The clinical and research opportunities and challenges of 7T MRI in each subtopic are set out as a roadmap. Specific MRI sequences for each subtopic were implemented in a pilot study presented in this report. Results show that a large multisite 7T imaging network with highly advanced and harmonized imaging sequences is feasible and may enable future multicentre ultrahigh-field MRI studies and clinical trials.
Discussion: The EUFIND network can be a major driver for advancing clinical neuroimaging research using 7T and for identifying use-cases for clinical applications in neurodegeneration.
| Original language | English |
|---|---|
| Pages (from-to) | 538-549 |
| Number of pages | 12 |
| Journal | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring |
| Volume | 11 |
| DOIs | |
| Publication status | Published - Dec 2019 |
Keywords
- Alzheimer's disease (AD)
- Magnetic resonance imaging (MRI)
- Mild cognitive impairment (MCI)
- Parkinson's disease (PD)
- Subjective cognitive decline (SCD)
- Ultrahigh-field MRI
- Vascular dementia
Fingerprint
Dive into the research topics of 'European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, 12.2019, p. 538-549.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND)
AU - Düzel, Emrah
AU - Acosta-Cabronero, Julio
AU - Berron, David
AU - Biessels, Geert Jan
AU - Björkman-Burtscher, Isabella
AU - Bottlaender, Michel
AU - Bowtell, Richard
AU - Buchem, Mark V
AU - Cardenas-Blanco, Arturo
AU - Boumezbeur, Fawzi
AU - Chan, Dennis
AU - Clare, Stuart
AU - Costagli, Mauro
AU - de Rochefort, Ludovic
AU - Fillmer, Ariane
AU - Gowland, Penny
AU - Hansson, Oskar
AU - Hendrikse, Jeroen
AU - Kraff, Oliver
AU - Ladd, Mark E
AU - Ronen, Itamar
AU - Petersen, Esben
AU - Rowe, James B
AU - Siebner, Hartwig
AU - Stoecker, Tony
AU - Straub, Sina
AU - Tosetti, Michela
AU - Uludag, Kamil
AU - Vignaud, Alexandre
AU - Zwanenburg, Jaco
AU - Speck, Oliver
N1 - Funding Information: The GUFI network was founded at the end of 2013 supported by the German Research Foundation. System reproducibility in human subjects has been compared within the network to validate multicentre brain imaging at 7T, known as the “traveling heads” study [61] . High reproducibility was found across all sites, but differences in intersite versus intrasite reproducibility were identified and assigned to hardware differences. Funding Information: The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z). CRMBM 7T program received funding from France Life Imaging (ANR-11-INBS-0006), Investissements d'Avenir (ANR-11-EQPX-0001), Aix-Marseille University Excellence Initiative A*MIDEX (grant ANR-11-IDEX-0001-02). Funding Information: This publication is an outcome of an EU Joint Programme?Neurodegenerative Disease Research (JPND) working group (see www.jpnd.eu). The working group was supported through the German Federal Ministry of Education and Research (BMBF, funding code 01ED1620) under the aegis of JPND. E D?zel receives funding from the Human Brain Project (European Union's Horizon 2020 research and Innovation Program under specific grant agreement No. 720270, SGA1/2, SP3, WP 3.3.1), DFG (SFB 779, A07), DFG (SFB 1315, B06) and the MRC (Project 538374 F69 to E D?zel). The Wellcome Centre for Human Neuroimaging is supported by core funding from the Wellcome (203147/Z/16/Z). JBR is supported by the Wellcome Trust (103838) and Medical Research Council (SUAG/004/91365). The research of Jeroen Hendrikse has received funding from the European Research Council under the European Union's Horizon 2020 Program (H2020)/ERC grant agreement n?637024 (HEARTOFSTROKE) and H2020 grant agreement No 666881, SVDs@target. Jeroen Hendrikse is supported by the Netherlands Organization for Scientific Research (NWO) under grant n?91712322. The research of Jaco Zwanenburg has received funding from the European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant agreement n?337333 (SmallVesselMRI).The UK7T Network is funded by MRC Partnership Grant MR/N008537/1. The Wellcome Centre for Integrative Neuroimaging is supported by core funding from the Wellcome Trust (203139/Z/16/Z). CRMBM 7T program received funding from France Life Imaging (ANR-11-INBS-0006), Investissements d'Avenir (ANR-11-EQPX-0001), Aix-Marseille University Excellence Initiative A*MIDEX (grant ANR-11-IDEX-0001-02). Mark E. Ladd and Oliver Speck acknowledge support from the German Research Foundation (DFG) for funding of the German Ultrahigh Field Imaging (GUFI) network, grant no. LA 1325/7-1 and SP 632/9-1. Authors' contributions: The authors contributed according to their role in the EUFIND consortium as outlined in the Appendix. Funding Information: Mark E. Ladd and Oliver Speck acknowledge support from the German Research Foundation (DFG) for funding of the German Ultrahigh Field Imaging (GUFI) network, grant no. LA 1325/7-1 and SP 632/9-1 . Funding Information: This publication is an outcome of an EU Joint Programme—Neurodegenerative Disease Research (JPND) working group (see www.jpnd.eu ). The working group was supported through the German Federal Ministry of Education and Research ( BMBF , funding code 01ED1620 ) under the aegis of JPND. E Düzel receives funding from the Human Brain Project (European Union's Horizon 2020 research and Innovation Program under specific grant agreement No. 720270, SGA1/2, SP3, WP 3.3.1), DFG (SFB 779, A07), DFG (SFB 1315, B06) and the MRC (Project 538374 F69 to E Düzel). The Wellcome Centre for Human Neuroimaging is supported by core funding from the Wellcome (203147/Z/16/Z). JBR is supported by the Wellcome Trust (103838) and Medical Research Council (SUAG/004/91365). The research of Jeroen Hendrikse has received funding from the European Research Council under the European Union's Horizon 2020 Program (H2020)/ERC grant agreement n°637024 (HEARTOFSTROKE) and H2020 grant agreement No 666881, SVDs@target. Jeroen Hendrikse is supported by the Netherlands Organization for Scientific Research (NWO) under grant n° 91712322 . The research of Jaco Zwanenburg has received funding from the European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant agreement n°337333 (SmallVesselMRI).The UK7T Network is funded by MRC Partnership Grant MR/N008537/1. Funding Information: Established in 2015 and funded by the UK Medical Research Council, this network aims to develop a platform for multicentre trials at 7T, enable multivendor studies and produce “work-horse” protocols. In a similar way to GUFI, the UK7T network has carried out a “traveling head” study with 10 participants across 5 sites, using a range of harmonized protocols including structural and functional measures. Initial data show that, as well as matching protocol parameters as much as possible, it is essential to standardize the various calibration steps (transmit power, B0 shim), to improve uniformity [63] . At present, QA procedures and a common phantom are also being disseminated among the UK7T partners. Publisher Copyright: © 2018 The Authors
PY - 2019/12
Y1 - 2019/12
N2 - Introduction: The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists.Methods: EUFIND combined consensus workshops and data sharing for multisite analysis, focusing on 7 core topics: clinical applications/clinical research, highest resolution anatomy, functional imaging, vascular systems/vascular pathology, iron mapping and neuropathology detection, spectroscopy, and quality assurance. Across these topics, EUFIND considered standard operating procedures, safety, and multivendor harmonization.Results: The clinical and research opportunities and challenges of 7T MRI in each subtopic are set out as a roadmap. Specific MRI sequences for each subtopic were implemented in a pilot study presented in this report. Results show that a large multisite 7T imaging network with highly advanced and harmonized imaging sequences is feasible and may enable future multicentre ultrahigh-field MRI studies and clinical trials.Discussion: The EUFIND network can be a major driver for advancing clinical neuroimaging research using 7T and for identifying use-cases for clinical applications in neurodegeneration.
AB - Introduction: The goal of European Ultrahigh-Field Imaging Network in Neurodegenerative Diseases (EUFIND) is to identify opportunities and challenges of 7 Tesla (7T) MRI for clinical and research applications in neurodegeneration. EUFIND comprises 22 European and one US site, including over 50 MRI and dementia experts as well as neuroscientists.Methods: EUFIND combined consensus workshops and data sharing for multisite analysis, focusing on 7 core topics: clinical applications/clinical research, highest resolution anatomy, functional imaging, vascular systems/vascular pathology, iron mapping and neuropathology detection, spectroscopy, and quality assurance. Across these topics, EUFIND considered standard operating procedures, safety, and multivendor harmonization.Results: The clinical and research opportunities and challenges of 7T MRI in each subtopic are set out as a roadmap. Specific MRI sequences for each subtopic were implemented in a pilot study presented in this report. Results show that a large multisite 7T imaging network with highly advanced and harmonized imaging sequences is feasible and may enable future multicentre ultrahigh-field MRI studies and clinical trials.Discussion: The EUFIND network can be a major driver for advancing clinical neuroimaging research using 7T and for identifying use-cases for clinical applications in neurodegeneration.
KW - Alzheimer's disease (AD)
KW - Magnetic resonance imaging (MRI)
KW - Mild cognitive impairment (MCI)
KW - Parkinson's disease (PD)
KW - Subjective cognitive decline (SCD)
KW - Ultrahigh-field MRI
KW - Vascular dementia
UR - https://www.scopus.com/pages/publications/85069944986
U2 - 10.1016/j.dadm.2019.04.010
DO - 10.1016/j.dadm.2019.04.010
M3 - Article
C2 - 31388558
SN - 2352-8729
VL - 11
SP - 538
EP - 549
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
ER -